Two-Year SYNTAX Data Show Comparable Safety Outcomes For Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents And Bypass Surgery

Boston Scientific Corporation (NYSE: BSX) announced two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the TAXUS(®) Express(®) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.